High-purity TB-500 (Thymosin Beta 4) peptide for advanced tissue regeneration and recovery research. 99%+ purity with comprehensive analytical testing. Ideal for studying cardiac repair, wound healing, and cellular migration mechanisms.
TB-500 (Thymosin Beta-4) 10mg – Lab Research Supply
Sale!
Anti-Inflammatory Research Peptides, etc, Longevity & Metabolic Research Peptides, Neuroprotective Research Peptides, Peptides, Recovery & Healing Peptides
TB-500 (Thymosin Beta-4) 10mg – Lab Research Supply
$123.00 / month – $1,450.00
High-purity TB-500 (Thymosin Beta 4) peptide for advanced tissue regeneration and recovery research. 99%+ purity with comprehensive analytical testing. Ideal for studying cardiac repair, wound healing, and cellular migration mechanisms.
SKU: N/A Categories: Anti-Inflammatory Research Peptides, etc, Longevity & Metabolic Research Peptides, Neuroprotective Research Peptides, Peptides, Recovery & Healing Peptides Tags: BPC-157, TB-500 (Thymosin Beta-4) 10mg Brand: PrymaLab
-
| Weight | 0.1 lbs |
|---|
Be the first to review “TB-500 (Thymosin Beta-4) 10mg – Lab Research Supply” Cancel reply
Related products
-
-
Anti-Inflammatory Research PeptidesTirzepatide 30mg – Lab Research Supply
$510.00 / month – $6,000.00 Select options This product has multiple variants. The options may be chosen on the product pageRated 0 out of 5 -
-
Anti-Inflammatory Research PeptidesRetatrutide 20mg – Lab Research Supply
$493.00 / month – $5,800.00 Select options This product has multiple variants. The options may be chosen on the product pageRated 0 out of 5 -
-
Anti-Inflammatory Research PeptidesRetatrutide 10mg – Lab Research Supply
$493.00 / month – $5,800.00 Select options This product has multiple variants. The options may be chosen on the product pageRated 0 out of 5 -
-
Anti-Inflammatory Research PeptidesTirzepatide 45mg – Lab Research Supply
$739.50 / month – $8,700.00 Select options This product has multiple variants. The options may be chosen on the product pageRated 0 out of 5

Reviews
There are no reviews yet.